Who is sponsoring NCT04554524?

NCT04554524 is sponsored by Tang-Du Hospital.

What drugs are being tested in NCT04554524?

Interventions in NCT04554524: Chemotherapy+Pembrolizumab..

What condition does NCT04554524 study?

NCT04554524 studies Thymoma and Thymic Carcinoma.

Is NCT04554524 still recruiting?

NCT04554524 is currently status unknown. Last updated 28 October 2020.

Last reviewed 2020-10-28 · How we verify

NCT04554524

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma

Status unknown Phase 4 Last updated 28 October 2020

What this trial tests

Phase 4 trial testing Chemotherapy+Pembrolizumab. in Thymoma and Thymic Carcinoma in 40 participants. Status unknown.

Timeline

27 August 2020

Primary endpoint
30 July 2024

30 July 2024

Quick facts

Lead sponsor	Tang-Du Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	27 August 2020
Primary completion	30 July 2024
Estimated completion	30 July 2024
Sites	1 location across China

Drugs / interventions tested

Chemotherapy+Pembrolizumab. — full drug profile →

Conditions studied

Thymoma and Thymic Carcinoma — all drugs for Thymoma and Thymic Carcinoma →

Sponsor

Tang-Du Hospital

Who can join

18 and older, any sex, with Thymoma and Thymic Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigational, single arm study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
Ao YQ, Gao J, Wang S, Jiang JH, et al · · 2023 · cited 32× · PMID 37055838 · DOI 10.1186/s12943-023-01772-4
Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions.
Rajan A, Sivapiromrat AK, McAdams MJ. · · 2024 · cited 12× · PMID 38611047 · DOI 10.3390/cancers16071369
Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours.
Dumoulin DW, Bironzo P, Passiglia F, Scagliotti GV, et al · · 2023 · cited 9× · PMID 36754434 · DOI 10.1183/16000617.0174-2022
Update on thymic epithelial tumors: a narrative review.
Cabezón-Gutiérrez L, Pacheco-Barcia V, Carrasco-Valero F, Palka-Kotlowska M, et al · · 2024 · cited 8× · PMID 38881809 · DOI 10.21037/med-23-47
Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report.
Nishii Y, Furuhashi K, Ito K, Sakaguchi T, et al · · 2022 · cited 5× · PMID 35890187 · DOI 10.3390/ph15070889
Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report.
Thomas QD, Basse C, Luporsi M, Girard N. · · 2021 · cited 5× · PMID 35127529 · DOI 10.3389/fonc.2021.814544
A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road.
Yu F, Gu Z, Zhang X, Xu N, et al · · 2024 · cited 4× · PMID 38730630 · DOI 10.3390/cancers16091680
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors.
Kareff SA, Samtani S, Burotto M, Prasad V, et al · · 2021 · cited 3× · PMID 34590006 · DOI 10.1016/j.jtocrr.2021.100149

Verify or expand the search:

Other recruiting trials for Thymoma and Thymic Carcinoma

Currently open trials in the same condition.

NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting

Other Tang-Du Hospital trials

Trials by the same sponsor.

NCT07528235 — An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intraven · Phase 1 · not yet recruiting
NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
NCT07354061 — Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT07327736 — Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT · NA · not yet recruiting
NCT07452601 — Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04554524 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tang-Du Hospital
Last refreshed: 28 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04554524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing